Prasher P, Singh M, Mudila H. Silver nanoparticles as antimicrobial therapeutics: current perspectives and future challenges.
3 Biotech 2018;
8:411. [PMID:
30237958 PMCID:
PMC6138003 DOI:
10.1007/s13205-018-1436-3]
[Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2018] [Accepted: 09/10/2018] [Indexed: 12/11/2022] Open
Abstract
Utility of silver metal in antimicrobial therapy is an accepted practice since ages that faded with time because of the identification of a few silver resistant strains in the contemporary era. A successive development of antibiotics soon followed. However, due to an indiscriminate and unregulated use coupled with poor legal control measures and a dearth of expertise in handling the critical episodes, the antibiotics era has already seen a steep decline in the past decades due to the evolution of multi-drug resistant 'superbugs' which pose a sizeable challenge to manage with. Due to limited options in the pipeline and no clear strategy in the forefront, the aspirations for novel, MDR focused drug discovery to target the 'superbugs' arose which once again led to the rise of AgNPs in antimicrobial research. In this review, we have focused on the green routes for the synthesis of AgNPs, the mode of microbial inhibition by AgNPs, synergistic effect of AgNPs with antibiotics and future challenges for the development of nano-silver-based therapeutics.
Collapse